Sex: M
Vaccine: COVID19
Symptoms: COVID-19, SARS-CoV-2 test
Clinical narrative: COVID-19; This spontaneous case was reported by a physician and describes the occurrence of COVID-19 (COVID-19) in an adult male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Drug allergy.    On an unknown date, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced COVID-19 (COVID-19). The patient was treated with NIRMATRELVIR, RITONAVIR (PAXLOVID) from 19-May-2022 to 23-May-2022 for COVID-19, at an unspecified dose and frequency. At the time of the report, COVID-19 (COVID-19) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 25-May-2022, SARS-CoV-2 test: negative (Negative) Negative. On 27-May-2022, SARS-CoV-2 test: positive (Positive) Positive. On an unknown date, SARS-CoV-2 test: result pending Result pending.     For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were reported.  It was reported that patient was not taking any other medications/products within 2 weeks of starting COVID-19 treatment.  Reporter reported that patient took Paxlovid 5 days, 2 days post last dose tested negative by Antigen test, 1 day later started to have very mild symptoms again, next morning tested positive on antigen test.  Device date  was reported as 27 May 2022.  Company comment: This is a spontaneous case concerning a adult male patient of unknown age with no relevant medical history, who experienced the unexpected non-serious AESI event of Covid-19. The event occurrence was unknown with respect to the third dose of mRNA-1273 vaccine administration. Allegedly the event was described as, patient took Nirmatrelvir + Ritonavir (Paxlovid) for treatment of Covid-19 for 5 days. Patient was tested negative by antigen test 2 days after the last dose of Paxlovid. However, after 1 day the patient started to experience very mild symptoms again. The next morning patient was tested positive on antigen test. Patient underwent PCR test with pending result. No other information surrounding the event was reported. The outcome of the event was unknown. The current Covid-19 pandemic remain confounder for the event. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.; Sender's Comments: This is a spontaneous case concerning a adult male patient of unknown age with no relevant medical history, who experienced the unexpected non-serious AESI event of Covid-19. The event occurrence was unknown with respect to the third dose of mRNA-1273 vaccine administration. Allegedly the event was described as, patient took Nirmatrelvir + Ritonavir (Paxlovid) for treatment of Covid-19 for 5 days. Patient was tested negative by antigen test 2 days after the last dose of Paxlovid. However, after 1 day the patient started to experience very mild symptoms again. The next morning patient was tested positive on antigen test. Patient underwent PCR test with pending result. No other information surrounding the event was reported. The outcome of the event was unknown. The current Covid-19 pandemic remain confounder for the event. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.